Compare TLX & HIW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TLX | HIW |
|---|---|---|
| Founded | 2015 | 1978 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.4B |
| IPO Year | 2024 | 1995 |
| Metric | TLX | HIW |
|---|---|---|
| Price | $10.79 | $29.62 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 10 |
| Target Price | $19.60 | ★ $32.33 |
| AVG Volume (30 Days) | 469.9K | ★ 1.1M |
| Earning Date | 10-15-2026 | 10-27-2026 |
| Dividend Yield | N/A | ★ 6.78% |
| EPS Growth | N/A | ★ 54.26 |
| EPS | N/A | ★ 0.29 |
| Revenue | N/A | ★ $806,112,000.00 |
| Revenue This Year | $15.69 | $7.34 |
| Revenue Next Year | $13.80 | $3.44 |
| P/E Ratio | $150.33 | ★ $102.05 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.28 | $20.45 |
| 52 Week High | $13.11 | $35.44 |
| Indicator | TLX | HIW |
|---|---|---|
| Relative Strength Index (RSI) | 43.29 | 44.24 |
| Support Level | $10.01 | $28.45 |
| Resistance Level | $11.48 | $31.08 |
| Average True Range (ATR) | 0.33 | 0.72 |
| MACD | -0.14 | -0.05 |
| Stochastic Oscillator | 3.37 | 44.07 |
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
Highwoods Properties Inc is a fully integrated office REIT that owns, develops, acquires, leases, and manages office properties mainly in the best business districts of Atlanta, Charlotte, Dallas, Nashville, Orlando, Raleigh, Richmond, and Tampa. Its principal business is the operation, acquisition, and development of rental office properties, with no material inter-segment transactions. The Company evaluates performance by geographic location, and the operating results by geographic grouping are regularly reviewed by the chief operating decision maker. The core portfolio consists mainly of office properties in its key markets, with the majority of revenue derived from its Raleigh properties.